Patents by Inventor Linda K. Joliffe

Linda K. Joliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDR-GRAFTED ANTI-TISSUE FACTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20100298544
    Abstract: The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Application
    Filed: June 10, 2010
    Publication date: November 25, 2010
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-grafted anti-tissue factor antibodies and methods of use thereof
    Patent number: 7777018
    Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: August 17, 2010
    Assignee: Centocor, Inc.
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-grafted anti-tissue factor antibodies and methods of uses there of
    Patent number: 7544790
    Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: June 9, 2009
    Assignee: Centocor, Inc.
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-Grafted Anti-Tissue Factor Antibodies and Methods of Use Thereof
    Publication number: 20080226628
    Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Application
    Filed: October 29, 2007
    Publication date: September 18, 2008
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-grafted anti-tissue factor antibodies and methods of use thereof
    Patent number: 7235380
    Abstract: The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: June 26, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito